
浏览全部资源
扫码关注微信
400037 重庆,陆军军医大学(第三军医大学)第二附属医院全军肿瘤研究所
[孙建国,E-mail: sunjg09@aliyun.comSUN Jianguo, E-mail:sunjg09@aliyun.com
收稿:2018-12-19,
修回:2019-03-10,
纸质出版:2019-07-15
移动端阅览
孔锐, 李奉, 郑林鹏, 等. 外周血中性粒细胞与淋巴细胞比率对NSCLC患者放疗效果的预测价值[J]. 第三军医大学学报, 2019,41(13):1261-1266.
Rui KONG, Feng LI, Linpeng ZHENG, et al. Predictive value of peripheral blood neutrophil to lymphocyte ratio in radiotherapeutic efficacy for NSCLC patients[J]. Journal of Third Military Medical University, 2019, 41(13): 1261-1266.
孔锐, 李奉, 郑林鹏, 等. 外周血中性粒细胞与淋巴细胞比率对NSCLC患者放疗效果的预测价值[J]. 第三军医大学学报, 2019,41(13):1261-1266. DOI: 10.16016/j.1000-5404.201812155.
Rui KONG, Feng LI, Linpeng ZHENG, et al. Predictive value of peripheral blood neutrophil to lymphocyte ratio in radiotherapeutic efficacy for NSCLC patients[J]. Journal of Third Military Medical University, 2019, 41(13): 1261-1266. DOI: 10.16016/j.1000-5404.201812155.
目的
2
探讨放疗前后外周血中性粒细胞与淋巴细胞比率(neutrophil to lymphocyte ratio,NLR)及其变化(ΔNLR)对晚期非小细胞肺癌(non-small cell lung cancer,NSCLC)患者放疗效果的预测价值。
方法
2
回顾性分析2011年3月至2016年5月本院行单纯放疗有完整随访资料的70例晚期NSCLC患者的临床资料,近期疗效分放疗敏感(PR+CR)组和非敏感(SD+PD)组,远期疗效以中位PFS为临界值分两组,分别检测各组放疗前后的血常规。以中位NLR为临界值分为高低两组,以放疗后NLR升高或降低分组,分别对比各组近期疗效的差别。
结果
2
放疗前NLR及其他血细胞指标与放疗敏感性、无进展生存期(progression-free survival,PFS)无相关性(
P
>
0.05)。放疗后NLR、ΔNLR与近期疗效呈负相关(
P
<
0.05),而与PFS无明显相关;放疗后NLR中位值为4.93,当NLR<4.93时,客观缓解率(ORR)为69%,NLR≥4.93时,ORR为37%;与放疗前比较,放疗后NLR降低(ΔNLR<0)组ORR为71%,而放疗后NLR升高(ΔNLR≥0)组ORR为45%。放疗后PLR、MLR及ΔPLR、ΔMLR也与近期疗效呈负相关(
P
<
0.05),且放疗后PLR、MLR与NLR存在一致性,ΔPLR、ΔMLR与ΔNLR存在一致性(
r
>0.5,
P
<
0.001)。
结论
2
放疗后的NLR、ΔNLR可作为与放疗近期疗效相关的预测指标。
Objective
2
To investigate the predictive value of neutrophil to lymphocyte ratio (NLR) in the peripheral blood and its changes (ΔNLR) after radiotherapy in advanced non-small cell lung cancer (NSCLC) patients.
Methods
2
The clinical data of 70 patients with advanced NSCLC who received simple radiotherapy in our hospital from March 2011 to June 2016 with complete follow-up data were retrospectively analyzed. The patients were divided into 2 groups based on the short-term efficacy: the radiotherapy sensitivity (PR+CR) group and non-sensitivity (SD+PD) group. They were also divided into 2 groups based on the long-term efficacy with median progression-free survival (PFS) as the critical value. Blood routine test was carried out before and after radiotherapy
and the results was compared between the 2 groups. Then with NLR as the critical value
the patients were divided into 2 groups. Differences in short-term efficacy were compared between those with increased NLR and those with decreased NLR.
Results
2
Before radiotherapy
NLR and other blood cell parameters had no correlation with radiosensitivity or PFS (
P
>
0.05). After radiotherapy
NLR and ΔNLR were negatively correlated with short-term efficacy (
P
<
0.05)
but was not correlated with PFS. After radiotherapy
NLR median value was 4.93
and objective response rate (ORR) was 69% when NLR
<
4.93; and was 37% when ≥4.93. In the group with decreased NLR (ΔNLR
<
0) after radiotherapy
ORR was 71%; in the group with increased NLR (ΔNLR≥0) after radiotherapy
ORR was 45%. Platelet to lymphocyte ratio (PLR)
monocytes to lymphocyte ratio (MLR)
ΔPLR and ΔMLR were also negatively correlated with short-term efficacy after radiotherapy (
P
<
0.05)
and PLR
MLR and NLR were consistent
while ΔPLR
ΔMLR and ΔNLR were also consistent after radiotherapy (
r
>
0.5
P
<
0.001).
Conclusion
2
After radiotherapy both NLR and ΔNLR can be used as predictive indicators for the short-term efficacy of radiotherapy in NSCLC patients.
TISSOT C, GAY P, BRUN C, et al . Novel insights into the systemic treatment of lung cancer malignant pleural effusion[J ] . Clin Respir J, 2019, 13(3): 131-138. DOI:10.1111/crj.13005.
WOOD D E, KAZEROONI E A, BAUM S L, et al . Lung cancer screening, version 3.2018, NCCN clinical practice guidelines in oncology[J ] . J Natl Compr Canc Netw, 2018, 16(4): 412-441. DOI:10.6004/jnccn.2018.0020.
CHENG M, JOLLY S, QUARSHIE W O, et al . Modern radiation further improves survival in non-small cell lung cancer: An analysis of 288, 670 patients[J ] . J Cancer, 2019, 10(1): 168-177. DOI:10.7150/jca.26600.
XU Z J, YAN Y L, XIAO L F, et al . Radiosensitizing effect of diosmetin on radioresistant lung cancer cells via Akt signaling pathway[J ] . PLoS ONE, 2017, 12(4): e0175977. DOI:10.1371/journal.pone.0175977..
MANTOVANI A, ALLAVENA P, SICA A, et al . Cancer-related inflammation[J ] . Nature, 2008, 454(7203): 436-444. DOI:10.1038/nature07205.
KIM T H, ROWAT A C, SLOAN E K. Neural regulation of cancer: from mechanobiology to inflammation[J]. Clin Transl Immunol, 2016, 5(5): e78. DOI:10.1038/cti.2016.18.
FERNANDES J V, COBUCCI R N, JATOBÁ C A, et al . The role of the mediators of inflammation in cancer development[J ] . Pathol Oncol Res, 2015, 21(3): 527-534. DOI:10.1007/s12253-015-9913-z.
TEMPLETON A J, MCNAMARA M G, ŠERUGA B, et al . Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: A systematic review and meta-analysis[J ] . J Natl Cancer Inst, 2014, 106(6): dju124. DOI:10.1093/jnci/dju124.
SUN H, HU P, DU J, et al . Predictive value of inflammatory indexes on the chemotherapeutic response in patients with unres ectable lung cancer: A retrospective study[J ] . Oncol Lett, 2018, 15(3): 4017-4025. DOI:10.3892/ol.2018.7781.
MUNN L L. Cancer and inflammation[J]. WIREs Syst Biol Med, 2017, 9(2): e1370. DOI:10.1002/wsbm.1370.
ZHANG H, XIA H G, ZHANG L M, et al . Clinical significance of preoperative neutrophil-lymphocyte vs platelet-lymphocyte ratio in primary operable patients with non-small cell lung cancer[J ] . Am J Surg, 2015, 210(3): 526-535. DOI:10.1016/j.amjsurg.2015.03.022..
SCILLA K A, BENTZEN S M, LAM V K, et al . Neutrophil-lymphocyte ratio is a prognostic marker in patients with locally advanced (stage ⅢA and ⅢB) non-small cell lung cancer treated with combined modality therapy[J ] . Oncologist, 2017, 22(6): 737-742. DOI:10.1634/theoncologist.2016-0443.
MOSES K, BRANDAU S. Human neutrophils: Their role in cancer and relation to myeloid-derived suppressor cells[J]. Semin Immunol, 2016, 28(2): 187-196. DOI:10.1016/j.smim.2016.03.018.
ZHOU X, DU Y P, HUANG Z B, et al . Prognostic value of PLR in various cancers: A meta-analysis[J ] . PLoS ONE, 2014, 9(6): e101119. DOI:10.1371/journal.pone.0101119.
SOYDAL C, KESKIN O, KUCUK O N, et al . Prognostic factors for prediction of survival of hepatocellular cancer patients after selective internal radiation therapy[J ] . Ann Nucl Med, 2015, 29(5): 426-430. DOI:10.1007/s12149-015-0962-x.
GRIVENNIKOV S I, GRETEN F R, KARIN M. Immunity, inflammation, and cancer[J]. Cell, 2010, 140(6): 883-899. DOI:10.1016/j.cell.2010.01.025.
HANAHAN D, COUSSENS L M. Accessories to the crime: functions of cells recruited to the tumor microenvironment[J]. Cancer Cell, 2012, 21(3): 309-322. DOI:10.1016/j.ccr.2012.02.022.
YODYING H, MATSUDA A, MIYASHITA M, et al . Prognostic significance of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in oncologic outcomes of esophageal cancer: A systematic review and meta-analysis[J ] . Ann Surg Oncol, 2016, 23(2): 646-654. DOI:10.1245/s10434-015-4869-5.
XUE T C, JIA Q A, GE N L, et al . Imbalance in systemic inflammation and immune response following transarterial chemoembolization potentially increases metastatic risk in huge hepatocellular carcinoma[J ] . Tu mor Biol, 2015, 36(11): 8797-8803. DOI: 10.1007/s13277-015-3632-7.
FAN W, ZHANG Y, WANG Y, et al . Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as predictors of survival and metastasis for recurrent hepatocellular carcinoma after transarterial chemoembolization[J ] . PLoS ONE, 2015, 10(3): e0119312. DOI:10.1371/journal.pone.0119312.
MIZUNUMA M, YOKOYAMA Y, FUTAGAMI M, et al . The pretreatment neutrophil-to-lymphocyte ratio predicts therapeutic response to radiation therapy and concurrent chemoradiation therapy in uterine cervical cancer[J ] . Int J Clin Oncol, 2015, 20(5): 989-996. DOI:10.1007/s10147-015-0807-6.
PENG W, LI C, WEN T F, et al . Neutrophil to lymphocyte ratio changes predict small hepatocellular carcinoma survival[J ] . J Surg Res, 2014, 192(2): 402-408. DOI:10.1016/j.jss.2014.05.078.
TEMPLETON A J, KNOX J J, LIN X, et al . Change in neutrophil-to-lymphocyte ratio in response to targeted therapy for metastatic renal cell carcinoma as a prognosticator and biomarker of efficacy[J ] . Eur Urol, 2016, 70(2): 358-364. DOI:10.1016/j.eururo.2016.02.033.
LALANI A A, XIE W, MARTINI D J, et al . Change in Neutrophil-to-lymphocyte ratio (NLR) in response to immune checkpoint blockade for metastatic renal cell carcinoma[J ] . J Immunother Cancer, 2018, 6(1): 5. DOI:10.1186/s40425-018-0315-0.
JIN F, HAN A, SHI F, et al . The postoperative neutrophil-to-lymphocyte ratio and changes in this ratio predict survival after the complete resection of stage I non-small cell lung cancer[J ] . Oncotargets Ther, 2016, 9:6529-6537. DOI: 10.2147/OTT.S117290.
0
浏览量
0
下载量
0
CSCD
关联资源
相关文章
相关作者
相关机构
京公网安备11010802024621